Icon

DUZALLO (nda209203)- (200MG;200MG,300MG;200MG)

ALLOPURINOL; LESINURAD IRONWOOD PHARMS INC
200MG;200MG,300MG;200MG
No Yes
2032-Feb-29 Expired
None None
None No
DUZALLO, a combination of lesinurad, a URAT1 inhibitor, and allopurinol, a xanthine oxidase inhibitor, is indicated for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.
0 0 0
Total Other Developers None
Drugs with Suitability No
200MG;200MG ** ** - - -
300MG;200MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.